TG Therapeutics Inc (NASDAQ:TGTX), announced that as part of a broader agreement with Jubilant Biosys (“Jubilant”), an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech company, to develop and commercialize Jubilant’s novel BET inhibitor program in the field of hematological malignancies.  Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors.  The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.

Under the terms of the agreement, TG Therapeutics will pay an up-front licensing fee of $1 million and make additional payments contingent on certain preclinical, clinical, and regulatory milestones, including commercial milestones totaling up to approximately $177 million and a single-digit royalty on net sales.  TG Therapeutics will also provide funding to support certain targeted research efforts at Jubilant Biosys.

Mr. Michael S. Weiss, Executive Chairman, Interim CEO and President stated, “We are very excited to add this BET inhibitor program to our growing portfolio of agents targeting hematological malignancies.  BET inhibitors have shown early promise in the treatment of relapsed and refractory Non-Hodgkin lymphomas, which remains a significant area of unmet medical need. There is emerging preclinical data showing BET inhibitors may enhance the activity of immuno-oncology agents, such as anti-PD-1/PD-L1 antibodies, providing multiple opportunities for us to combine this novel mechanism within our portfolio.  Epigenetic targeted agents, especially BET inhibitors, have been an area of great interest of ours for some time and are particularly attractive to us because of their effects on c-Myc driven tumors, like aggressive GCB-subtype DLBCL, an area we have seen early activity with TGR-1202 and our proprietary combination referred to as TG-1303.  We want to thank our collaborators at Checkpoint for introducing us to this opportunity.” Mr. Weiss continued, “As we prepare to launch our registration directed studies in DLBCL and Follicular Lymphoma, we continue to look toward next steps in the evolution of patient care and believe the best outcome will be achieved only through the combination of multiple novel agents.” (Original Source)

Shares of TG Therapeutics closed yesterday at $7.22, down $0.56 or -7.20%. TGTX has a 1-year high of $19.05 and a 1-year low of $6.95. The stock’s 50-day moving average is $8.71 and its 200-day moving average is $9.77.

On the ratings front, TG Therapeutics has been the subject of a number of recent research reports. In a report issued on May 19, FBR analyst Edward White reiterated a Buy rating on TGTX. Separately, on May 11, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $28.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward White and Jonathan Aschoff have a total average return of -3.8% and -10.5% respectively. White has a success rate of 55.8% and is ranked #3332 out of 3869 analysts, while Aschoff has a success rate of 37.9% and is ranked #3843.

The street is mostly Bullish on TGTX stock – All the 4 analysts who cover the stock suggest a Buy rating . The 12-month average price target assigned to the stock is $22.00, which implies an upside of 205% from current levels.

TG Therapeutics, Inc. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.